The comparative efficacy and safety of peginterferon Alpha-2a vs. 2b for the treatment of chronic HCV infection: A meta-analysis

Hepatitis Monthly

Volumn 10, Issue 2, 2010, Pages 121-131

  Alavian, Seyed Moayed ^a   Behnava, Bita ^a   Tabatabaei, Seyed Vahid ^a  

^a BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

HCV; Meta analysis; Pegasys; Peginterferon alpha 2a; Peginterferon alpha 2b; PegIntron; Systematic review

Indexed keywords

PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ANEMIA; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COCHRANE LIBRARY; DEPRESSION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FLU LIKE SYNDROME; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INFORMATION RETRIEVAL; MEDLINE; MENTAL DISEASE; META ANALYSIS; NEUTROPENIA; REVIEW; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; VIRUS LOAD;

EID: 77954881726     PISSN: 1735143X     EISSN: 17353408     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. Alavian SM, Adibi P, Zali MR. Hepatitis C virus in Iran: Epidemiology of an emerging infection. Arch Iran Med. 2005;8(2):84-90.
2. Alavian SM, Mirmomen S, Bagheri-Lankarani K, Adibi P, Merat S. Management of Hepatitis C Infection (Regional Guideline). Hepat Mon. 2004;4(4):1-10.
3. Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol. 2007;13(17):2436-41.
4. Alberti A, Benvegnu L. Management of hepatitis C. J Hepatol. 2003;38 Suppl1:S104-18.
5. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis. 2005;5(9):558-67.
6. Teoh NC, Farrell GC. Management of chronic hepatitis C virus infection: a new era of disease control. Intern Med J. 2004;34(6):324-37.
7. Poynard T, Leroy V, Mathurin P, Cohard M, Opolon P, Zarski JP. Treatment of chronic hepatitis C by interferon for longer duration than six months. Dig Dis Sci. 1996;41(12 Suppl):99S-102S.
8. Hoofnagle JH, di Bisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med. 1997;336(5):347-56.
9. Poynard T, Leroy V, Cohard M, et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology. 1996;24(4):778-89.
10. Lin R, Roach E, Zimmerman M, Strasser S, Farrell GC. Interferon alfa-2b for chronic hepatitis C: effects of dose increment and duration of treatment on response rates. Results of the first multicentre Australian trial. Australia Hepatitis C Study Group. J Hepatol. 1995;23(5):487-96.
11. Carithers RL, Jr., Emerson SS. Therapy of hepatitis C: meta-analysis of interferon alfa-2b trials. Hepatology. 1997;26(3 Suppl 1):83S-8S.
12. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med. 1998;339(21):1485-92.
13. Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet. 1998;352(9138):1426-32.
14. Lai MY, Kao JH, Yang PM, et al. Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C. Gastroenterology. 1996;111(5):1307-12.
15. Ferenci P, Formann E, Laferl H, et al. Randomized, double-blind, placebo-controlled study of peginterferon alfa-2a (40KD) plus ribavirin with or without amantadine in treatment-naive patients with chronic hepatitis C genotype 1 infection. J Hepatol. 2006;44(2):275-82.
16. Bosques-Padilla F, Trejo-Estrada R, Campollo-Rivas O, et al. Peginterferon alfa-2a plus ribavirin for treating chronic hepatitis C virus infection: analysis of Mexican patients included in a multicenter international clinical trial. Ann Hepatol. 2003;2(3):135-9.
17. Hadziyannis SJ, Sette H, Jr., Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140(5):346-55.
18. Jacobson IM, Brown RS, Jr., Freilich B, et al. Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial. Hepatology. 2007;46(4):971-81.
19. Chou R, Carson S, Chan BK. Pegylated interferons for chronic hepatitis C virus infection: an indirect analysis of randomized trials. J Viral Hepat. 2008.
20. Gluud LL. Bias in clinical intervention research. Am J Epidemiol. 2006;163(6):493-501.
21. Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. Introduction to meta-analysis. 1st ed. Chichester: John Wiley & Sons Ltd; 2009.
22. Petitti DB. Meta-Analysis, Decision Analysis, and Cost-Effectiveness Analysis: Methods for Quantitative Synthesis in Medicine. 2nd ed. New York: Oxford University Press; 2000.
23. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557-60.
24. Ascione A, Luca MD, Tartaglione MT, et al. Peginterferon Alphalfa-2a Plus Ribavirin Is More Effective Than Peginterferon Alphalfa-2b Plus Ribavirin for Treating Chronic Hepatitis C Virus Infection. Gastroenterology. 2010;138(1):116-22.
25. Scotto G, Fazio V, Fornabaio C, et al. Early and sustained virological response in non-responders with chronic hepatitis C: a randomized open-label study of pegylated interferon-alpha-2a versus pegylated interferon-alpha-2b. Drugs. 2008;68(6):791-801.
26. Scotto G, Fazio V, Fornabaio C, et al. Peg-interferon alpha-2a versus Peg-interferon alpha-2b in nonresponders with HCV active chronic hepatitis: a pilot study. J Interferon Cytokine Res. 2008;28(10):623-9.
27. McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009;361(6):580-93.
28. Rumi M, Aghemo A, Prati GM, et al. Randomized Study of Peginterferon-alpha2a Plus Ribavirin vs Peginterferon-alpha2b Plus Ribavirin in Chronic Hepatitis C. Gastroenterology. 2010;138(1):108-15.
29. Yenice N, Mehtap O, Gumrah M, Arican N. The efficacy of pegylated interferon alpha 2a or 2b plus ribavirin in chronic hepatitis C patients. Turk J Gastroenterol. 2006;17(2):94-8.
30. Silva M, Poo J, Wagner F, et al. A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE). J Hepatol. 2006;45(2):204-13.
31. Bruno R, Sacchi P, Ciappina V, et al. Viral dynamics and pharmacokinetics of peginterferon alpha-2a and peginterferon alpha-2b in naive patients with chronic hepatitis c: a randomized, controlled study. Antivir Ther. 2004;9(4):491-7.
32. Laguno M, Cifuentes C, Murillas J, et al. Randomized trial comparing pegylated interferon alpha-2b versus pegylated interferon alpha-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients. Hepatology. 2009;49(1):22-31.
33. Sporea I, Danila M, Sirli R, Popescu A, Laza A, Baditoiu L. Comparative study concerning the efficacy of Peg-IFN alpha-2a versus Peg-IFN alpha-2b on the early virological response (EVR) in patients with chronic viral C hepatitis. J Gastrointestin Liver Dis. 2006;15(2):125-30.
34. Mangia A, Minerva N, Bacca D, et al. Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial. Hepatology. 2008;47(1):43-50.
35. Ascione A, De Luca M, Tartaglione MT, et al. Peginterferon alpha-2a plus ribavirin versus peginterferon alpha-2b plus ribavirin in naive patients with chronic hepatitis C virus infection: results of a prospective randomised trial. J Hepatol. 2008;48 (Suppl 2):S370.
36. Berak H, Kolakowska-Rzadzka A, Wasilewski M, et al. Comparison of efficacy of treatment with peginterferon alfa-2a plus ribavirin versus peginterferon alfa-2b plus ribavirin among patients chronically infected with non 2/3 HCV genotypes with low and high pretreatment viral load. Hepatology. 2007;46(1 Suppl 1):385A-6A.
37. Di Bisceglie AM, Ghalib RH, Hamzeh FM, Rustgi VK. Early virologic response after peginterferon alpha-2a plus ribavirin or peginterferon alpha-2b plus ribavirin treatment in patients with chronic hepatitis C. J Viral Hepat. 2007;14(10):721-9.
38. Escudero A, Rodriguez F, Serra MA, Del Olmo JA, Montes F, Rodrigo JM. Pegylated alpha-interferon-2a plus ribavirin compared with pegylated alpha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study. J Gastroenterol Hepatol. 2008;23(6):861-6.
39. Craxi A, Piccinino F, Alberti A, et al. Predictors of SVR in naive HCV G1 patients in real life practice: the PROBE. J Hepatol. 2008;48(Suppl 2):S291.
40. Thuy PT, Dat HT. Comparison between the two peginterferons alfa in the treatment of chronic hepatitis C. Hepatology. 2007;46(1 Suppl 1):387A-8A.
41. Mauss S, Berger F, Schmutz G. Peginterferon alfa-2a versus peginterferon alfa-2b in the treatment of chronic hepatitis C. Hepatology. 2004;40(4 Suppl 1):730A.
42. Lee S, Kim IH, Kim SH, et al. Efficacy and Tolerability of Pegylated Interferon-a(2a) plus Ribavirin versus Pegylated Interferon-a(2b) plus Ribavirin in Treatment-Naive Chronic Hepatitis C Patients. Intervirology. 2010;53(3):146-53.
43. Vispo E, Barreiro P, Rodriguez-Novoa S, et al. Distinct hepatitis C virus kinetics in HIV-infected patients treated with ribavirin plus either pegylated interferon alpha2a or alpha2b. Antivir Ther. 2008;13(4):511-7.
44. Backus LI, Boothroyd DB, Phillips BR, Mole LA. Predictors of response of US veterans to treatment for the hepatitis C virus. Hepatology. 2007;46(1):37-47.
45. Witthoeft T, Hueppe D, John C, et al. Efficacy and tolerability of peginterferon alfa-2a or alfa-2b plus ribavirin in the daily routine treatment of patients with chronic hepatitis C in Germany: The PRACTICE Study. J Viral Hepat. 2010. [in press].
46. Hammoud I, Sherbondy MH, Moonka D, et al. Peginterferon alpha-2b versus peginterferon alpha-2a in the treatment of chronic hepatitis C infection. Hepatology. 2007;46(1 Suppl 1):386A-7A.
47. Bailon P, Won CY. PEG-modified biopharmaceuticals. Expert Opin Drug Deliv. 2009;6(1):1-16.
48. Veronese FM, Mero A. The impact of PEGylation on biological therapies. BioDrugs. 2008;22(5):315-29.
49. Foser S, Schacher A, Weyer KA, et al. Isolation, structural characterization, and antiviral activity of positional isomers of monopegylated interferon alpha-2a (PEGASYS). Protein Expr Purif. 2003;30(1):78-87.
50. Bailon P, Palleroni A, Schaffer CA, et al. Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. Bioconjug Chem. 2001;12(2):195-202.
51. Foster GR. Review article: pegylated interferons: chemical and clinical differences. Aliment Pharmacol Ther. 2004;20(8):825-30.
52. Dhalluin C, Ross A, Huber W, et al. Structural, kinetic, and thermodynamic analysis of the binding of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers to the extracellular domain of the receptor IFNAR2. Bioconjug Chem. 2005;16(3):518-27.
53. Formann E, Jessner W, Bennett L, Ferenci P. Twice-weekly administration of peginterferon-alpha-2b improves viral kinetics in patients with chronic hepatitis C genotype 1. J Viral Hepat. 2003;10(4):271-6.
54. Foster GR. Pegylated interferons for the treatment of chronic hepatitis C: pharmacological and clinical differences between peginterferon-alpha-2a and peginterferon-alpha-2b. Drugs. 2010;70(2):147-65.
55. Antonini MG, Babudieri S, Maida I, et al. Incidence of neutropenia and infections during combination treatment of chronic hepatitis C with pegylated interferon alfa-2a or alfa-2b plus ribavirin. Infection. 2008;36(3):250-5.
56. Schulz KF, Grimes DA. Allocation concealment in randomised trials: defending against deciphering. Lancet. 2002;359(9306):614-8.